Salomon & Ludwin’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.58M Sell
1,691
-100
-6% -$101K 0.14% 76
2025
Q4
$1.87M Buy
1,791
+483
+37% +$462K 0.16% 70
2025
Q3
$1.1M Buy
1,308
+189
+17% +$141K 0.1% 85
2025
Q2
$872K Sell
1,119
-21
-2% -$16.3K 0.09% 85
2025
Q1
$942K Buy
1,140
+396
+53% +$330K 0.1% 80
2024
Q4
$574K Sell
744
-370
-33% -$306K 0.06% 95
2024
Q3
$987K Sell
1,114
-34
-3% -$30.6K 0.1% 81
2024
Q2
$1.04M Sell
1,148
-23,342
-95% -$18.7M 0.12% 78
2024
Q1
$19.1M Sell
24,490
-4,303
-15% -$3.06M 1.64% 20
2023
Q4
$15.5M Hold
28,793
1.61% 22
2023
Q3
$15.5M Sell
28,793
-148
-0.5% -$76.3K 1.61% 22
2023
Q2
$13.6M Sell
28,941
-33
-0.1% -$13.8K 1.44% 22
2023
Q1
$9.95M Sell
28,974
-1,083
-4% -$365K 1.19% 26
2022
Q4
$11M Buy
30,057
+1,301
+5% +$461K 1.39% 26
2022
Q3
$9.3M Buy
28,756
+1,200
+4% +$380K 1.39% 25
2022
Q2
$8.93M Sell
27,556
-25
-0.1% -$7.5K 1.38% 23
2022
Q1
$7.9M Sell
27,581
-66
-0.2% -$17K 1.15% 24
2021
Q4
$7.64M Buy
27,647
+24,860
+892% +$6.3M 1.08% 25
2021
Q3
$644K Buy
+2,787
New +$688K 0.1% 50
2020
Q1
Sell
-428
Closed -$56K 242
2019
Q4
$56K Buy
+428
New +$49.6K 0.01% 106
2019
Q2
Sell
-548
Closed -$71K 246
2019
Q1
$71K Buy
+548
New +$66.6K 0.01% 71

Other funds holding LLY

Salomon & Ludwin's LLY Position: Q1 2026 in Review

Salomon & Ludwin reduced its Eli Lilly (LLY) stake by 5.6% in Q1 2026, selling an estimated $101K and leaving 1,691 shares worth $1.58M. The position accounts for 0.14% of the portfolio, ranked #76.

Salomon & Ludwin first reported a position in LLY in Q1 2019 and has held it in 21 quarters since. The position peaked at $19.1M in Q1 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Salomon & Ludwin held 1,691 shares of Eli Lilly worth $1.58M as of Q1 2026.
  • Salomon & Ludwin sold 100 Eli Lilly shares in Q1 2026, an estimated $101K.
  • Eli Lilly made up 0.14% of Salomon & Ludwin's portfolio in Q1 2026, its #76 holding.
  • Salomon & Ludwin first reported a position in Eli Lilly in Q1 2019 and has held it in 21 quarters since.
  • Salomon & Ludwin's Eli Lilly position peaked at $19.1M in Q1 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.